A Critical Review of Biological Properties, Delivery Systems and Analytical/Bioanalytical Methods for Determination of Bevacizumab

Filippo, Leonardo Delello Di; Santos, Karen Cristina dos; Hanck-Silva, Gilmar; Lima, Felipe Tita de; Gremião, Maria Palmira Daflon; Chorilli, Marlus

doi:10.1080/10408347.2020.1743641

Cited by 9 publications

(6 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Far UV CD spectra are obtained in the range of 190–250 nm, with a signature peak at 218 nm for Far-UV CD spectra. The intensity of these distinctive peaks revealed the protein's intrinsic structural characteristics and showed through protein folding that these aromatic amino acids and disulfide bonds are present in the chemically inert surrounding [ 14 ]. The Far-UV CD study confirms antiparallel β-sheet as the prominent secondary structure of Bio-1 (40.9 ± 2.0%), Bio-2 (46.5 ± 2.0%) and Avt (44.1 ± 2.0%) control formulations , Fig.…”

Section: Resultsmentioning

confidence: 99%

Comparative stability study and aggregate analysis of Bevacizumab marketed formulations using advanced analytical techniques

Bana,

Sajeev,

Halder

et al. 2023

Heliyon

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Comparative stability study and aggregate analysis of Bevacizumab marketed formulations using advanced analytical techniques

Bana,

Sajeev,

Halder

et al. 2023

Heliyon

View full text Add to dashboard Cite

“…Consecutively, endothelial dysfunction can be influenced by the drugs that septic patients receive during therapy, not only directed related to sepsis, but also with other associated dysfunctions: anticoagulants, vasoactive, antihypertensives, calcium channel blockers, so endothelial alteration should be evaluated not only in the context of the underlying disease but as well as for the applied therapy [14,15]. Equally important is not only the proper administration but also the biological properties, pharmacokinetics and plasma levels of each of these drugs [16,17].…”

Section: Discussionmentioning

confidence: 99%

The Diagnostic and Prognostic Role of Vascular Endothelial Growth Factor C in Sepsis and Septic Shock

Almasy

Szederjesi

Grigorescu

et al. 2020

The Journal of Critical Care Medicine

View full text Add to dashboard Cite

IntroductionVariations in the expression of vascular endothelial growth factor (VEGF) could be used as a biomarker in critically ill patients with sepsis and septic shock. Inflammation potently upregulates VEGF-C expression via macrophages with an unpredictable response. This study aimed to assess one of the newer biomarkers (VEGF-C) in patients with sepsis or septic shock and its clinical value as a diagnostic and prognostic tool.Material and methodsThe study involved 142 persons divided into three groups. Group A consisted of fifty-eight patients with sepsis; Group B consisted of forty-nine patients diagnosed as having septic shock according to the Sepsis -3 criteria. A control group of thirty-five healthy volunteers comprised Group C. Severity scores, prognostic score and organ dysfunction score, were recorded at the time of enrolment in the study. The analysis included specificity and sensitivity of plasma VEGF-C for diagnosis of septic shock. Circulating plasma VEGF-C levels were correlated with the APACHE II, MODS and severity scores and mortality.ResultsThe mean (SD) plasma VEGF-C levels in septic shock patients (1374(789) pg./m), on vasopressors at the time of admission to the ICU, were significantly higher 1374(789)pg./mL, compared the mean (SD) plasma VEGF-C levels in sepsis patients (934(468) pg./mL); (p = 0.0005, Student’s t-test.) Plasma VEGF-C levels in groups A and B were shown to be significantly correlated with the APACHE II (r = 0.21, p = 0.02; r = 0.45, p = 0.0009) and MODS score (r = 0.29, p = 0.03; r = 0.4, p = 0.003). There was no association between plasma VEGF-C levels and mortality [p = 0.1]. The cut-off value for septic shock was 1010 pg./ml.ConclusionsVEGF-C may be used as a prognostic marker in sepsis and septic shock due to its correlation with APACHE II values and as an early marker to determine the likelihood of developing MODS. It could be used as an early biomarker for diagnosing patients with septic shock.

show abstract

“… 25 Vascular endothelial cells in boundary region rapidly up-regulate the expression of vascular endothelial growth factor (VEGF) to stimulate angiogenesis and supply blood flow and oxygen for repair. 26 But the neovascularization is immature due to lack of smooth muscle cell wall coating. The structural incompleteness of blood vessels makes them highly permeable, which facilitates the penetration of inflammatory cells and mediators.…”

Section: Microenvironmental Changes In Amimentioning

confidence: 99%

Application of locally responsive design of biomaterials based on microenvironmental changes in myocardial infarction

Wang,

Li,

Han

et al. 2023

iScience

View full text Add to dashboard Cite

A Critical Review of Biological Properties, Delivery Systems and Analytical/Bioanalytical Methods for Determination of Bevacizumab

Cited by 9 publications

References 47 publications

Comparative stability study and aggregate analysis of Bevacizumab marketed formulations using advanced analytical techniques

Comparative stability study and aggregate analysis of Bevacizumab marketed formulations using advanced analytical techniques

The Diagnostic and Prognostic Role of Vascular Endothelial Growth Factor C in Sepsis and Septic Shock

Application of locally responsive design of biomaterials based on microenvironmental changes in myocardial infarction

Contact Info

Product

Resources

About